A Study of a Combination of Trastuzumab and Capecitabine With or Without Pertuzumab in Patients With HER2-positive Metastatic Breast Cancer (PHEREXA)

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Drug: Capecitabine
Drug: Pertuzumab
Drug: Trastuzumab

Registration Number: NCT01026142

Lead Sponsor: Hoffmann-La Roche

Brief Summary: This randomized, two-arm study evaluated the efficacy and safety of a combination of trastuzumab and capecitabine with or without pertuzumab in patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer. The study population consisted of female patients, whose disease had progressed during or following previous trastuzumab therapy for metastatic disease. All patients in Arm A and Arm B received trastuzumab (8 mg/kg iv as loading dose and then 6 mg/kg iv every 3 weeks thereafter) and capecitabine oral twice daily for 14 days every 3 weeks (1250 mg/m2 twice daily in Arm A and 1000 mg/m2 twice daily in Arm B). In addition, patients in Arm B received pertuzumab (840 mg iv as loading dose and then 420 mg iv thereafter) every 3 weeks. Study treatment continued until disease progression or unacceptable toxicity.

Detailed Description: Not available

Recruitment & Eligibility

Status: COMPLETED

Sex: Female

Target Recruitment: 452

Inclusion Criteria

Adult female patients >/=18 years of age
Metastatic HER2 positive breast cancer
Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
Disease progression during or following trastuzumab-based therapy for 1st line metastatic breast cancer (trastuzumab must have been part of the last prior treatment regimen)
Prior treatment with taxane-containing regimen
Left ventricular ejection fraction (LVEF) >/=50 percent
For women of childbearing potential agreement to use highly effective non-hormonal form of contraception or two effective forms of non-hormonal contraception by patient and/or partner. Contraception must continue for duration of study treatment and for at least 6 months after last dose of study drug treatment

Exclusion Criteria

Prior treatment with pertuzumab or capecitabine
Concurrent treatment with other experimental drug
Concurrent immunotherapy or anticancer hormonal therapy
Serious concurrent disease (e.g. active infection, uncontrolled hypertension, cardiovascular disease)
Central nervous system (CNS) metastases, which are not well controlled
History of exposure to anthracycline cumulative dose equivalent to 360mg/m2
History of congestive heart failure of any New York Heart Association criteria, or serious cardiac arrhythmia requiring treatment
History of myocardial infarction within 6 months prior to randomization
History of LVEF decline to below 50% during or after prior trastuzumab therapy or other cardiac toxicity during previous trastuzumab treatment that necessitated discontinuation of trastuzumab
History of another cancer which could affect compliance or result interpretation
Inadequate organ function
Pregnant or breastfeeding women
life expectancy < 12 weeks

Study & Design

Study Type: INTERVENTIONAL

Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
B: Capecitabine + Trastuzumab + Pertuzumab	Capecitabine	-
B: Capecitabine + Trastuzumab + Pertuzumab	Pertuzumab	-
A: Capecitabine + Trastuzumab	Capecitabine	-
A: Capecitabine + Trastuzumab	Trastuzumab	-
B: Capecitabine + Trastuzumab + Pertuzumab	Trastuzumab	-

Primary Outcome Measures

Name	Time	Method
Progression Free Survival (Independent Assessment)	Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).	Progression Free Survival (PFS) was defined as the time from randomization to first documented disease progression (PD), as determined by an Independent Review Facility (IRF) using Response Evaluation Criteria in Solid Tumors (RECIST) version 1.0, or death from any cause, whichever occurred first. PD was defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. IRF review of tumor assessment ceased after the primary PFS analysis. The primary endpoint was analyzed after approximately 337 IRF-assessed PFS events were observed.

Secondary Outcome Measures

Name	Time	Method
Overall Survival (OS)	From randomization until death from any cause (up to 7.5 years).	Overall Survival (OS) was defined as the time from the date of randomization to the date of death from any cause. The results of the final OS analysis are presented here. Participants who were alive or lost to follow-up at the time of the analysis were censored at the last known alive date. Participants with no postbaseline information were censored at the time of randomization plus 1 day. Prior to the final data analysis cut-off, it was ensured that all participants who were in survival follow-up had been contacted as recently as possible within the last 3 months to confirm current survival status.
Overall Survival (OS) Rate Based on a 2-year Truncated Analysis	From randomization until death from any cause (up to 2 years)	The Overall Survival (OS) 2-year truncated analysis is the Kaplan-Meier estimate of the percentage of participants who were surviving at 2 years. OS is defined as the time from the date of randomization to the date of death from any cause, with censoring of all events and follow-up beyond the end of the second year.
Investigator Assessment Progression-Free Survival (PFS)	Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 7.5 years).	Investigator Assessment Progression-Free Survival (PFS) was defined as the time from randomization to the first documented progressive disease, as determined by the investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.0, or death from any cause, whichever occurred first. PD is defined as at least a 20% increase in the sum of the longest diameter (LD) of target lesions taking as reference the smallest sum LD recorded since the treatment started or the appearance of one or more new lesions; or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
Time to Progression (TTP) Based Upon Independent Review Facility (IRF) Assessment	Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).	Time to Progression (TTP) was defined as time between randomization and the first occurrence of progressive disease (PD), based on IRF assessment.
Time to Treatment Failure (TTF) Based Upon Independent Review Facility (IRF) Assessment	Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).	Time to Treatment Failure (TTF) was defined as time between randomization and date of disease progression based on independent review, death, or withdrawal of treatment due to adverse events, withdrawn informed consent, refusal of treatment/failure to cooperate, or failure to return, whichever occurred first.
Overall Objective Response Rate (ORR)	Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).	Overall Objective Response Rate is based upon investigator and IRF assessments. Objective Response Rate (ORR) was defined as the percentage of participants with a confirmed complete response (CR) or partial response (PR) among those who had measurable disease at baseline. CR was defined as the disappearance of all target lesions. PR was defined as at least a 30% decrease in the sum of the longest diameter (LD) of target lesions, taking as reference the baseline sum LD.
Clinical Benefit Rate (CBR)	Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).	Clinical Benefit Rate is based upon Independent Review Facility (IRF) assessments; defined as the percentage of participants a complete response (CR), partial response (PR), or stable disease for at least 8 cycles or 6 months.
Duration of Objective Response	Tumor assessments every 9 weeks from randomization until Week 27, then every 12 weeks thereafter, until IRF-determined PD, initiation of alternative anticancer medication, or death (up to 5.5 years).	Duration of Objective Response was defined for the subpopulation of responders as time from first Independent Review Facility (IRF)-assessed complete response (CR) or partial response (PR) to subsequent first documented, IRF-confirmed evidence of disease progression. Only participants with an objective response were included in the analysis of duration of objective response.

Trial Locations

Locations (190): Fundación Investigar
🇦🇷
Buenos Aires, Argentina
Hospital Britanico; Oncologia
🇦🇷
Buenos Aires, Argentina
Instituto FIDES
🇦🇷
La Plata, Argentina
Instituto de Investigaciones Clínicas Quilmes
🇦🇷
Quilmes, Argentina
Instituto de Oncología de Rosario
🇦🇷
Rosario, Argentina
ISIS Clinica Especializada
🇦🇷
Santa Fe, Argentina
A.Ö. Landesschwerpunktkrankenhaus Krems; Abtl. F. Innere Med.
🇦🇹
Krems, Austria
Landeskrankenhaus Rankweil; Interne E
🇦🇹
Rankweil, Austria
Lkh Salzburg - Univ. Klinikum Salzburg; Iii. Medizinische Abt.
🇦🇹
Salzburg, Austria
Medizinische Universität Wien; Univ.Klinik für Innere Medizin I - Abt. für Onkologie
🇦🇹
Wien, Austria
Scroll for more (180 remaining)
Fundación Investigar
🇦🇷Buenos Aires, Argentina